^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PI3Kβ inhibitor

    Related drugs:
    3d
    Integrative bioinformatics and machine learning approach unveils potential biomarkers linking coronary atherosclerosis and glutamine metabolism-associated gene. (PubMed, J Cardiothorac Surg)
    This study successfully discovered nine GlnMgs that are associated with AS. These findings provide valuable insights into potential novel biomarkers for AS and offer prospects for monitoring disease progression.
    Journal
    |
    MIR21 (MicroRNA 21) • NOS3 (Nitric oxide synthase 3) • SIRT4 (Sirtuin 4)
    |
    acalisib (GS-9820)
    4d
    STARS: Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke (clinicaltrials.gov)
    P2, N=80, Recruiting, The Florey Institute of Neuroscience and Mental Health | Suspended --> Recruiting
    Enrollment open
    |
    AZD6482
    9d
    Co-STARS: Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion (clinicaltrials.gov)
    P2, N=78, Recruiting, ThromBio Pty. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AZD6482
    18d
    PDCD1 as a targetable immune checkpoint hub: therapeutic insights for ibrutinib-resistant CLL management. (PubMed, Clin Exp Med)
    Using two independent datasets (GSE249956 and GSE98206), differentially expressed genes (DEGs) were identified between ibrutinib-resistant and sensitive CLL samples. In the broader context, PD-1 expression in CLL cells is linked to active proliferation and immune escape. Overall, our findings emphasize PDCD1's central role in ibrutinib resistance through immune checkpoint pathways and support the rationale for combining BTK inhibitors with immune checkpoint blockade therapies in resistant CLL cases.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • ITGB2 (Integrin Subunit Beta 2) • CD1C (CD1c Molecule)
    |
    PD-L1 expression
    |
    Imbruvica (ibrutinib) • acalisib (GS-9820)
    28d
    PI3K inhibitors: Efficacy in diverse cancer forms. (PubMed, Cancer Treat Res Commun)
    The PI3K inhibitors GDC-0032 and INK1117 for PI3K-α and AZD8186 for PI3K-β are now being studied in clinical trials. Research on the clinical development, therapeutic utility, and structural insights of new PI3K inhibitors is the main emphasis of this review. The inhibitors have been shown promising anticancer activity relationships.
    Review • Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)
    |
    taselisib (GDC-0032) • AZD8186 • serabelisib (MLN1117)
    1m
    EAY131-N: Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2025 --> Dec 2026
    Trial completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    GSK2636771
    1m
    PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PTEN (Phosphatase and tensin homolog) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)
    |
    ER positive • HR positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    docetaxel • AZD8186
    2ms
    EAY131-P: Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2025 --> Dec 2026
    Trial completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    GSK2636771
    2ms
    Mendelian randomization combined with single-cell sequencing analysis revealed prognostic genes related to myeloid cell differentiation in prostate cancer and experimental verification. (PubMed, Front Immunol)
    The HRG and LRG suggested notable differences in sensitivity to 86 drugs such as AZD8186...The in vitro results were consistent with the results of bioinformatics analysis, indicating that the analysis results were reliable. This study identified 5 prognostic genes and a risk model, suggesting a fresh thought on the subsequent development of PCa related drugs.
    Journal
    |
    FASN (Fatty acid synthase) • TLR3 (Toll Like Receptor 3) • RACGAP1 (Rac GTPase activating protein 1) • BMP2 (Bone Morphogenetic Protein 2)
    |
    AZD8186
    3ms
    NK cell-related genes-driven novel molecular subtyping and prognostic signatures for Wilms tumor: uncovering the therapeutic potential of TGX-221 and biomarker role of HS2ST1. (PubMed, Front Oncol)
    Moreover, TGX-221 represents a promising novel therapeutic candidate, while HS2ST1 serves as a potential prognostic biomarker. These findings collectively provide tools for risk stratification and targeted therapy, advancing precision oncology for WT.
    Journal
    |
    PPP3CA (Protein Phosphatase 3 Catalytic Subunit Alpha)
    |
    TGX-221
    3ms
    A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors. (PubMed, ESMO Open)
    The combination of AZD8186 and docetaxel was generally well tolerated, with the exception of neutropenia, which was effectively managed with the use of growth factor. Limited clinical activity was observed.
    P1 data • Journal
    |
    PTEN (Phosphatase and tensin homolog) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)
    |
    docetaxel • AZD8186
    3ms
    Co-STARS: Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion (clinicaltrials.gov)
    P2, N=78, Not yet recruiting, ThromBio Pty. Ltd. | Initiation date: May 2025 --> Oct 2025 | Trial primary completion date: Jun 2026 --> Dec 2026
    Trial initiation date • Trial primary completion date
    |
    AZD6482